Editas Medicine (EDIT) said late Thursday that it will focus on in vivo CRISPR-edited medicines and end the development of reni-cel to optimize cost structure and extend cash runway into Q2 2027.
The strategic transition will help the company accelerate in vivo human proof of concept in about two years, the company said.
Editas said it will also eliminate 65% of its workforce over the next six months. Chief Medical Officer Baisong Mei will leave the company, while Jessica Hopfield will become chair of the board on Dec. 31.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。